The site features the company's access pathways program designed to reduce the barriers associated with prescribing Qudexy XR, and offers healthcare professionals the tools necessary to help their patients start, stay, and save on Qudexy XR therapy, including an informational video, a guide on how to get started and a patient enrollment form.
Qudexy XR (topiramate) Extended-Release Capsules is a prescription medicine used to prevent migraine headaches in adults and adolescents 12 years and older, as an initial monotherapy to treat partial-onset seizures and primary generalised tonic-clonic seizures in adults and children two years and older, and as adjunctive therapy to treat certain types of seizures.
Upsher-Smith is a pharmaceutical company that provide a consistent supply of quality, affordable generic medications.
In June 2017, Upsher-Smith was acquired by Sawai Pharmaceutical Co., Ltd., a large publicly traded generics company in Japan that had been seeking entry into the US market.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US